Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Pabinger

Hamostaseologie

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Hamostaseologie|November 5, 2004
[Thrombophilia]I Pabinger
Hamostaseologie|August 9, 2011
Treatment and secondary prevention of venous thromboembolism in cancer patients. Current strategies and new therapeutic optionsC Ay, I Pabinger
Hamostaseologie|August 9, 2011
Risk of venous thromboembolism and primary prophylaxis in cancer. Should all patients receive thromboprophylaxis?I Pabinger, C Ay
Hamostaseologie|March 6, 2015
VTE risk assessment in cancer. Who needs prophylaxis and who does not?C Ay, I Pabinger
Hamostaseologie|January 31, 2006
Thrombophilia and pregnancy complicationsR Vormittag, I Pabinger
Hamostaseologie|July 28, 2011
Clinical significance of circulating microparticles for venous thromboembolism in cancer patientsJ Thaler, C Ay, I Pabinger
Hamostaseologie|December 6, 2013
Platelets in cancer and thrombosisJ Riedl, I Pabinger, C Ay
Hamostaseologie|January 10, 2009
[Update thrombophilia]E Lindhoff-Last, B Luxembourg, I Pabinger
Hamostaseologie|May 1, 2009
Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITIK Thom, Christoph Male, J Falger, et al.
Hamostaseologie|October 11, 2011
[Venous thrombembolism in tumour patients]I Pabinger, B Alt-Epping, F Demarmels Biasutti, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Hamostaseologie|November 5, 2004
[Thrombophilia]I Pabinger
Hamostaseologie|August 9, 2011
Treatment and secondary prevention of venous thromboembolism in cancer patients. Current strategies and new therapeutic optionsC Ay, I Pabinger
Hamostaseologie|August 9, 2011
Risk of venous thromboembolism and primary prophylaxis in cancer. Should all patients receive thromboprophylaxis?I Pabinger, C Ay
Hamostaseologie|March 6, 2015
VTE risk assessment in cancer. Who needs prophylaxis and who does not?C Ay, I Pabinger
Hamostaseologie|January 31, 2006
Thrombophilia and pregnancy complicationsR Vormittag, I Pabinger
Hamostaseologie|July 28, 2011
Clinical significance of circulating microparticles for venous thromboembolism in cancer patientsJ Thaler, C Ay, I Pabinger
Hamostaseologie|December 6, 2013
Platelets in cancer and thrombosisJ Riedl, I Pabinger, C Ay
Hamostaseologie|January 10, 2009
[Update thrombophilia]E Lindhoff-Last, B Luxembourg, I Pabinger
Hamostaseologie|May 1, 2009
Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITIK Thom, Christoph Male, J Falger, et al.
Hamostaseologie|October 11, 2011
[Venous thrombembolism in tumour patients]I Pabinger, B Alt-Epping, F Demarmels Biasutti, et al.
Pageof 2